Multiple myeloma involving central nervous system: high frequency of chromosome 17p13.1 (p53) deletions

被引:98
作者
Chang, H [1 ]
Sloan, S [1 ]
Li, D [1 ]
Stewart, AK [1 ]
机构
[1] Univ Toronto, Princess Margaret Hosp, Univ Hlth Network, Dept Med Oncol & Hematol, Toronto, ON M5G 2M9, Canada
关键词
myeloma; central nervous system; fluorescence in situ hybridization; p53; deletions; prognostic factor;
D O I
10.1111/j.1365-2141.2004.05199.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Central nervous system (CNS) involvement is an unusual manifestation in multiple myeloma (MM). The molecular basis of CNS myeloma is poorly understood. MM is characterized by translocations involving the immunoglobulin heavy chain (IgH) locus and frequent 13q deletions. Alterations of p53 or c-myc in MM may represent secondary changes associated with disease progression. We investigated nine patients with CNS MM using interphase fluorescence in situ hybridization (FISH) combined with immunofluorescence detection of the cytoplasmic light chain (cIg-FISH) for the presence of above genomic aberrations. Of nine patients studied, eight cases had hemizygous p53 deletion and 4 had 13q deletions. Of the patients with 13q deletions, two had IgH translocations, one involving 4p16.3 (FGFR3), the other involving 16q23 (c-maf). The high incidence of p53 deletions detected by cIg-FISH in CNS myeloma may be a marker for chromosomal instability, and may be associated with metastatic features of myeloma cells.
引用
收藏
页码:280 / 284
页数:5
相关论文
共 28 条
  • [1] A novel three-color, clone-specific fluorescence in situ hybridization procedure for monoclonal gammopathies
    Ahmann, GJ
    Jalal, SM
    Juneau, AL
    Christensen, ER
    Hanson, CA
    Dewald, GW
    Greipp, PR
    [J]. CANCER GENETICS AND CYTOGENETICS, 1998, 101 (01) : 7 - 11
  • [2] Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation
    Avet-Loiseau, H
    Facon, T
    Grosbois, B
    Magrangeas, F
    Rapp, MJ
    Harousseau, JL
    Minvielle, S
    Bataille, R
    [J]. BLOOD, 2002, 99 (06) : 2185 - 2191
  • [3] Avet-Loiseau H, 1999, GENE CHROMOSOME CANC, V24, P9, DOI 10.1002/(SICI)1098-2264(199901)24:1<9::AID-GCC2>3.0.CO
  • [4] 2-K
  • [5] Chromosome translocations in multiple myeloma
    Bergsagel, PL
    Kuehl, WM
    [J]. ONCOGENE, 2001, 20 (40) : 5611 - 5622
  • [6] INCIDENCE, PROGNOSTIC-SIGNIFICANCE AND THERAPEUTIC MODALITIES OF CENTRAL NERVOUS-SYSTEM INVOLVEMENT IN MULTIPLE-MYELOMA
    BRENNER, B
    CARTER, A
    TATARSKY, I
    GRUSZKIEWICZ, J
    PEYSER, E
    [J]. ACTA HAEMATOLOGICA, 1982, 68 (02) : 77 - 83
  • [7] CANCER PROGRESSION AND P53
    CARSON, DA
    LOIS, A
    [J]. LANCET, 1995, 346 (8981): : 1009 - 1011
  • [8] Frequent monoallelic loss of D13S319 in multiple myeloma patients shown by interphase fluorescence in situ hybridization
    Chang, H
    Bouman, D
    Boerkoel, CF
    Stewart, AK
    Squire, JA
    [J]. LEUKEMIA, 1999, 13 (01) : 105 - 109
  • [9] The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant
    Chang, H
    Sloan, S
    Li, D
    Zhuang, LH
    Yi, QL
    Chen, CI
    Reece, D
    Chun, K
    Stewart, AK
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2004, 125 (01) : 64 - 68
  • [10] Detection of chromosome 13q deletions and IgH translocations in patients with multiple myeloma by FISH: Comparison with karyotype analysis
    Chang, H
    Li, D
    Zhuang, LH
    Nie, E
    Bouman, D
    Stewart, AK
    Chun, K
    [J]. LEUKEMIA & LYMPHOMA, 2004, 45 (05) : 965 - 969